Maravai LifeSciences Holdings Non-GAAP EPS of -$0.03 beats by $0.03, revenue of $45.9M beats by $2.34M. * Maravai LifeSciences Holdings press release (MRVI): Q3 Non-GAAP EPS of -$0.03 beats by $0.03. * Revenue of $45.9M (+10.3% Y/Y) beats by $2.34M. * Net loss and Adjusted EBITDA (non-GAAP) were $(24.0) million and $5.8 million, respectively, for the third quarter of 2026, compared to net loss and Adjusted EBITDA (non-GAAP) of $(45.1) million and $(10.8) million, respectively, for the third quarter of 2025. Nine Months Ended September 30, 2026 Financial Results by Reporting Segment Revenue for the nine months ended September 30, 2026 increased 20.1% compared to the prior year period, driven by the following: * TriLink revenue increased 29.7% year-over-year, primarily driven by $14.3 million of high-volume CleanCap orders for commercial phase COVID vaccine programs in Q1 2026. Excluding COVID CleanCap revenue, TriLink base revenue grew 12.9% year-over-year with increased demand for Discovery mRNA and GMP consumables. * Cygnus revenue increased 3.8% year-over-year, driven by demand for HCP and ELISA kits. Net loss and Adjusted EBITDA (non-GAAP) were $(52.0) million and $34.8 million, respectively, for the nine months ended September 30, 2026, compared to net loss and Adjusted EBITDA (non-GAAP) of $(167.7) million and $(31.7) million, respectively, for the same period in the prior year. Updated Financial Guidance for Full Year 2026 Revenue for the full year 2026 is now expected to be in the range of $212.0 million to $216.0 million, up from the prior range of $205.0 million to $215.0 million. Adjusted EBITDA (non-GAAP) is now expected to be in the range of $40.0 million to $42.0 million, up from the prior range of $33.0 million to $35.0 million. Fresh Stock Ideas, Every Day Explore diverse investing perspectives with daily analysis from experts across the market.

TriLink BioTechnologies, part of Maravai LifeSciences, has opened a GMP enzyme manufacturing facility in Jupiter, Florida, to provide integrated supply of RNA manufacturing materials from research to commercial scale. The company shipped its first commercial GMP enzyme batch in June 2026. The facility addresses supply chain challenges for RNA therapeutics developers by offering coordinated sourcing of enzymes, nucleotides, cap analogues and tail technology from a single supplier. Previously, developers had to manage multiple vendors with different quality systems and timelines. TriLink's flagship product, GMP CleanScribe RNA Polymerase, reduces double-stranded RNA formation by up to 85% compared to standard enzymes, improving manufacturing efficiency and product quality. The integrated offering aims to simplify tech transfer and ensure material consistency throughout the development lifecycle.